Search clinical trials for: PARP Inhibitor

Total 67693 results

Sarah E Taylor
American Society of Clinical Oncology

Terminated

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

Ovarian Cancer

United States
Bristol-Myers Squibb

Terminated

Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV (DIMENSION)

Chronic Hepatitis C Infection

France, Germany, United States, Spain, Canada, Argentina, Mexico, Belgium, Italy, Russian Federation, United Kingdom, Poland
zr Pharma & GmbH

Completed

A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma

United States, Israel
zr Pharma & GmbH
Bristol-Myers Squibb; Foundation Medicine

Terminated

A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Endometrioid Adenocarcinoma | High Grade Serous Carcinoma | Primary Peritoneal Carcinoma

United States
zr Pharma & GmbH
Foundation Medicine; Myriad Genetics, Inc.

Completed

A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) (ARIEL2)

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

United States, Spain, Canada, Australia, United Kingdom, France
zr Pharma & GmbH
Foundation Medicine; Myriad Genetics, Inc.

Completed

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) (ARIEL3)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

United States, Spain, Belgium, Australia, Israel, Germany, France, United Kingdom, Italy, Canada, New Zealand
zr Pharma & GmbH

Completed

Pharmacokinetic Drug-Drug Interaction Study of Rucaparib (DDI)

Neoplasms

Poland
zr Pharma & GmbH

Completed

Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib (AME)

Solid Tumor

Hungary
zr Pharma & GmbH
Foundation Medicine

Completed

A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2)

Metastatic Castration Resistant Prostate Cancer

United States, Spain, United Kingdom, France, Australia, Belgium, Denmark, Israel, Germany, Ireland, Canada, Italy
zr Pharma & GmbH

Completed

Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor

Neoplasms

United Kingdom, Poland, Slovakia
zr Pharma & GmbH
Foundation Medicine

Completed

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

United Kingdom, United States, Israel, Spain, Italy, Czechia, Canada, Hungary, Poland, Russian Federation, Brazil, Ukraine
zr Pharma & GmbH
Foundation Medicine

Completed

A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer | Advanced Solid Tumor With Evidence of Germline or Somatic BRCA

United States, Israel, Spain, Canada, United Kingdom
zr Pharma & GmbH
Foundation Medicine

Terminated

Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (ATLAS)

Bladder Cancer | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Muscle Invasive Bladder Cancer | Ureter Carcinoma | Renal Pelvis Carcinoma | Urinary Bladder Carcinoma | Urethra Carcinoma

United States, Spain, France, Italy, Germany, United Kingdom
zr Pharma & GmbH

Completed

A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens

Advanced Solid Tumors

United Kingdom
zr Pharma & GmbH

Completed

Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives

Neoplasms

Poland, Slovakia, Hungary
University of Alabama at Birmingham

Withdrawn

Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer (PARP)

Ovarian Cancer Recurrent

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma | Stage IVA Oropharyngeal Carcinoma AJCC v7 | Stage IVB Oropharyngeal Carcinoma AJCC v7

United States
University Hospital, Caen

Completed

Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

Cancer

France
Tesaro, Inc.
European Network of Gynaecological Oncological Trial Groups (ENGOT); US Oncology... and other collaborators

Completed

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

Ovarian Neoplasms | Platinum Sensitive Ovarian Cancer

United States, Belgium, Sweden, Germany, Israel, Austria, Canada, Denmark, Spain, Italy, United Kingdom, Poland, France, Hungary, Norway
University of Arizona

Active, not recruiting

Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors

Breast Cancer

United States
Jonsson Comprehensive Cancer Center
BeiGene; Driven To Cure

Withdrawn

Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

Metastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Unresectable Renal Cell Carcinoma | Hereditary Leiomyomatosis and Renal Cell Carcinoma | Clear Cell Papillary Renal Neoplasm | Hereditary Papillary Renal Cell Carcinoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

Neuroendocrine Carcinoma | Small Cell Carcinoma | Extensive Stage Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Large Cell Lung Carcinoma

United States
National Cancer Institute (NCI)

Completed

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Breast Carcinoma | Metastatic Triple-Negative Breast Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Recurrent... and other conditions

United States
Tesaro, Inc.

Completed

Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer (COHORT-A)

Ovarian Neoplasm

United States
Sheba Medical Center

Completed

Efficacy and Safety of PARPi to Treat Pancreatic Cancer (10)

Pancreatic Cancer

Israel
Pfizer

Terminated

Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)

Ovarian Cancer

Korea, Republic of, United States, Singapore, Taiwan, Japan, Italy, Australia, Belgium, Ireland, Russian Federation
University of Texas Southwestern Medical Center

Completed

PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer

Breast Cancer | Ovarian Cancer

United States
Hellenic Cooperative Oncology Group

Active, not recruiting

Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer

Ovarian Cancer

Greece
Tesaro, Inc.

Active, not recruiting

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Ovarian Neoplasms

United States
Idience Co., Ltd.

Active, not recruiting

Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS) (VASTUS)

Solid Tumors | Homologous Recombination Deficiency | Homologous Recombination Repair Gene Mutation

Korea, Republic of
National Cancer Institute (NCI)

Active, not recruiting

Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery

Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Advanced Malignant Solid Neoplasm | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | Metastatic Malignant Solid Neoplasm | Triple-Negative Breast Carcinoma | Unresectable Solid Neoplasm | Metastatic Malignant Neoplasm | Unresectable... and other conditions

United States
Pfizer

Completed

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | NSCLC | Prostate Cancer | Advanced Solid Tumors | Solid Tumors

United States, Australia
Tesaro, Inc.
Merck Sharp & Dohme LLC

Completed

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO)

Neoplasms | Breast Cancer | Advanced Breast Cancer | Ovarian Cancer | Fallopian Tube Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Peritoneal Cancer | Stage IV Breast Cancer

United States
Tesaro, Inc.
European Organisation for Research and Treatment of Cancer - EORTC; Breast... and other collaborators

Terminated

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (BRAVO)

Ovarian Neoplasms | BRCA1 Gene Mutation | BRCA2 Gene Mutation | Neoplasms, Breast | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Carcinoma of Breast

United States, Spain, Belgium, Israel, United Kingdom, Italy, Poland, Canada, Hungary, Netherlands, France, Portugal, Greece, Iceland
AstraZeneca
European Network of Gynaecological Oncological Trial Groups (ENGOT)

Completed

A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. (OReO)

Epithelial Ovarian Cancer

Denmark, France, Germany, Italy, Spain, Poland, Belgium, Canada, United Kingdom, Israel, Norway
Jonsson Comprehensive Cancer Center
Medivation, Inc.; BioMarin Pharmaceutical; Translational Research in Oncology

Completed

PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Metastatic Cancer | Unspecified Adult Solid Tumor

United States
Tesaro, Inc.
Myriad Genetics, Inc.; Facing Our Risk of Cancer Empowered

Completed

A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens (QUADRA)

Ovarian Neoplasms | Ovarian Cancer

United States, Canada
Sanofi

Completed

Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma

Glioblastoma

United States
Duke University
AstraZeneca

Completed

Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) (DORA)

Triple Negative Breast Cancer

United States
Jiangsu HengRui Medicine Co., Ltd.

Terminated

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

Solid Tumor

China
Nordic Society of Gynaecological Oncology - Clinical...
Massachusetts General Hospital; University of Utah; European Network of Gynaecological... and other collaborators

Completed

Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer (AVANOVA)

Ovarian Cancer

United States, Denmark
Jiangsu HengRui Medicine Co., Ltd.
Peking University Cancer Hospital & Institute

Completed

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Ovarian Cancer | Triple Negative Breast Cancer

China
Hunan Cancer Hospital

Completed

Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer (ACTDNAGLT)

Metastatic Breast Cancer | Circulating Tumor DNA | Gene Abnormality
Calithera Biosciences, Inc

Terminated

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Clear Cell Renal Cell Carcinoma | Colorectal Cancer | Solid Tumor | CRC | TNBC - Triple-Negative Breast Cancer | ccRCC | RCC

United States
National Cancer Institute (NCI)

Completed

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

Neoplasms

United States
University of Pennsylvania

Terminated

Effect of PARP Inhibitors on Glomerular Filtration Rate

Breast Cancer | Ovarian Cancer | Solid Tumor

United States
Pfizer
Medivation, Inc.

Completed

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) (EMBRACA)

Breast Neoplasms | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

Korea, Republic of, United States, Australia, Spain, Belgium, France, Ireland, Taiwan, Poland, Germany, Israel, Brazil, United Kingdom, Italy, Russian Federation, Ukraine
AbbVie

Completed

Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

Metastatic Breast Cancer

United States, Argentina, Australia, Belgium, Brazil, Canada, Czechia, Denmark, Finland, France, Hungary, Israel, Netherlands, Norway, Poland, Romania, Russian Federation, Spain, Sweden, Ukraine
National Cancer Institute (NCI)
NRG Oncology

Completed

Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Carcinoma | Ovarian Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell... and other conditions

United States
Thomas Jefferson University
AstraZeneca

Active, not recruiting

Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences

Recurrent Breast Carcinoma | Metastatic Malignant Neoplasm in the Chest Wall

United States

Search clinical trials for: PARP Inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations